Sol-Gel Technologies Ltd.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IL0011417206
USD
40.70
1.97 (5.1%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

19.34 k

Shareholding (Mar 2025)

FII

17.75%

Held by 8 FIIs

DII

82.13%

Held by 0 DIIs

Promoter

0.00%

How big is Sol-Gel Technologies Ltd.?

22-Jun-2025

As of Jun 18, Sol-Gel Technologies Ltd. has a market capitalization of 19.51 million, with net sales of 12.10 million and a net profit of -13.05 million over the latest four quarters. Shareholder's funds are 28.85 million, and total assets are 35.85 million.

As of Jun 18, Sol-Gel Technologies Ltd. has a market capitalization of 19.51 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 12.10 million, while the sum of Net Profit for the same period is -13.05 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 28.85 million and Total Assets at 35.85 million.

Read More

What does Sol-Gel Technologies Ltd. do?

22-Jun-2025

Sol-Gel Technologies Ltd. is a clinical-stage dermatology company focused on developing topical drug products for skin diseases. As of March 2025, it has a market cap of $19.51 million, with net sales of $1 million and a net loss of $9 million.

Overview: <BR>Sol-Gel Technologies Ltd. is a clinical-stage dermatology company focused on developing and commercializing branded and generic topical drug products for the treatment of skin diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -9 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 19.51 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.82 <BR>Return on Equity: -64.66% <BR>Price to Book: 0.97<BR><BR>Contact Details: <BR>Address: Weizmann Science Park, 7, Golda Me'ir, NESS-ZIONA None: 7403650 <BR>Tel: ['972 8 9313433'] <BR>Fax: 972 8 9313434 <BR>Website: http://www.sol-gel.com

Read More

Who are in the management team of Sol-Gel Technologies Ltd.?

22-Jun-2025

As of March 2022, the management team of Sol-Gel Technologies Ltd. includes Chairman Mr. Moshe Arkin, CEO Dr. Alon Seri-Levy, Directors Mr. Itai Arkin, Ms. Hani Lerman, and independent Directors Dr. Shmuel Ben Zvi, Mr. Jerrold Gattegno, and Mr. Ran Gottfried. This diverse team oversees the company's governance and strategic direction.

As of March 2022, the management team of Sol-Gel Technologies Ltd. includes the following individuals:<BR><BR>- Mr. Moshe Arkin, Chairman of the Board<BR>- Dr. Alon Seri-Levy, Chief Executive Officer, Co-Founder, and Director<BR>- Mr. Itai Arkin, Director<BR>- Ms. Hani Lerman, Director<BR>- Dr. Shmuel Ben Zvi, Independent Director<BR>- Mr. Jerrold Gattegno, Independent Director<BR>- Mr. Ran Gottfried, Independent Director<BR><BR>This team comprises a mix of leadership roles and independent directors, contributing to the governance and strategic direction of the company.

Read More

Should I buy, sell or hold Sol-Gel Technologies Ltd.?

22-Jun-2025

Is Sol-Gel Technologies Ltd. overvalued or undervalued?

20-Sep-2025

As of March 10, 2023, Sol-Gel Technologies Ltd. is considered overvalued and has shifted from a fair to a risky valuation grade due to poor financial metrics, including negative returns and a high EV to EBITDA ratio compared to its peers.

As of 10 March 2023, the valuation grade for Sol-Gel Technologies Ltd. moved from fair to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.00 and an EV to Sales ratio of 0.30, which suggest limited growth potential in relation to its market price. Additionally, the company's negative ROCE of -388.12% and ROE of -64.66% further highlight its struggles in generating returns for shareholders.<BR><BR>In comparison to its peers, Sol-Gel Technologies Ltd. has a significantly higher EV to EBITDA ratio of -11.1084 compared to Assembly Biosciences, Inc. at -6.6467 and Societal CDMO, Inc. at 18.7985, indicating that it is not performing well relative to its industry counterparts. The overall financial health and performance metrics suggest that the company is overvalued in the current market context. There is no available return data to compare against the S&P 500, but the lack of positive returns reinforces the concerns surrounding its valuation.

Read More

Is Sol-Gel Technologies Ltd. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, Sol-Gel Technologies Ltd. shows a bullish trend with strong momentum indicators, despite a bearish monthly RSI and mildly bearish weekly OBV, while significantly outperforming the S&P 500 year-to-date and over the past year.

As of 4 September 2025, the technical trend for Sol-Gel Technologies Ltd. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. However, the monthly RSI is bearish, suggesting some weakness in price strength. The daily moving averages are bullish, supporting the overall positive outlook. Despite the bullish trend, the weekly OBV is mildly bearish, which could indicate some selling pressure. <BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 185.64% compared to the S&P 500's 12.22%, and a one-year return of 310.25% versus 17.14%. Overall, the current technical stance is bullish, with strong momentum indicators but some caution due to the bearish monthly RSI.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 0.67%

  • The company has been able to generate a Return on Equity (avg) of 0.67% signifying low profitability per unit of shareholders funds
2

Poor long term growth as Net Sales has grown by an annual rate of 12.38% over the last 5 years

 
3

Positive results in Jun 25

4

Risky - Negative EBITDA

5

High Institutional Holdings at 27.81%

6

Market Beating performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 77 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.75

stock-summary
Return on Equity

-10.70%

stock-summary
Price to Book

2.41

Revenue and Profits:
Net Sales:
17 Million
(Quarterly Results - Jun 2025)
Net Profit:
12 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
73.93%
0%
73.93%
6 Months
457.23%
0%
457.23%
1 Year
658.9%
0%
658.9%
2 Years
206.02%
0%
206.02%
3 Years
794.51%
0%
794.51%
4 Years
-45.22%
0%
-45.22%
5 Years
-54.98%
0%
-54.98%

Sol-Gel Technologies Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
12.38%
EBIT Growth (5y)
12.94%
EBIT to Interest (avg)
-17.36
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.82
Sales to Capital Employed (avg)
0.25
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
27.81%
ROCE (avg)
0.98%
ROE (avg)
0.67%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.00
EV to EBIT
-0.26
EV to EBITDA
-0.26
EV to Capital Employed
1.00
EV to Sales
0.30
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-388.12%
ROE (Latest)
-64.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.12%)

Foreign Institutions

Held by 8 Foreign Institutions (17.75%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 1,630.00% vs 233.33% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 231.82% vs -51.72% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "17.30",
          "val2": "1.00",
          "chgp": "1,630.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "11.20",
          "val2": "-9.10",
          "chgp": "223.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "11.60",
          "val2": "-8.80",
          "chgp": "231.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "650.60%",
          "val2": "-8,796.30%",
          "chgp": "944.69%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 618.75% vs -58.97% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 61.03% vs -82.55% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11.50",
          "val2": "1.60",
          "chgp": "618.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.80",
          "val2": "-29.00",
          "chgp": "59.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.60",
          "val2": "-27.20",
          "chgp": "61.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,041.30%",
          "val2": "-18,893.20%",
          "chgp": "1,785.19%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
17.30
1.00
1,630.00%
Operating Profit (PBDIT) excl Other Income
11.20
-9.10
223.08%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
11.60
-8.80
231.82%
Operating Profit Margin (Excl OI)
650.60%
-8,796.30%
944.69%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 1,630.00% vs 233.33% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 231.82% vs -51.72% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
11.50
1.60
618.75%
Operating Profit (PBDIT) excl Other Income
-11.80
-29.00
59.31%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-10.60
-27.20
61.03%
Operating Profit Margin (Excl OI)
-1,041.30%
-18,893.20%
1,785.19%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 618.75% vs -58.97% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 61.03% vs -82.55% in Dec 2023

stock-summaryCompany CV
About Sol-Gel Technologies Ltd. stock-summary
stock-summary
Sol-Gel Technologies Ltd.
Pharmaceuticals & Biotechnology
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
Company Coordinates stock-summary
Company Details
Weizmann Science Park, 7, Golda Me'ir , NESS-ZIONA None : 7403650
stock-summary
Tel: 972 8 9313433
stock-summary
Registrar Details